Ireland
--:--IST
Starting soon Not applicable

Psychological Intervention on Cold Executive Function and Academic Performance in University Women With Insomnia

NCT07529652 · tracked via the Priya Life Science Mexico tracker
Phase
Not applicable
Started
2026-08-30
Last updated
2026-04-14

Condition(s) studied

Insomnia

Investigational drug(s) / intervention(s)

Psychological Program to Improve Sleep Quality

Psychological Program to Improve Sleep Quality: The intervention consists of a structured psychological program designed to improve sleep quality and reduce insomnia symptoms in female university students. Sleep hygiene: Minimally invasive behavioral recommendations are implemented to establish healthy habits and routines that promote sleep onset and continuity. Relaxation techniques: Strategies are used to decrease physiological and cognitive activation prior to sleep. Stimulus control: This technique aims to reduce the negative association between the bedroom and difficulty sleeping. The intervention is delivered in a structured and supervised format, with the goal of promoting sustainable behavioral and cognitive changes that improve sleep quality. The intervention will be conducted weekly in group sessions lasting approximately one hour. The researcher will administer the intervention.

Study summary

Sleep disturbances, particularly insomnia, are highly prevalent among university women and are associated with impairments in executive functioning and academic performance. Women present higher rates of insomnia due to biological and psychosocial factors. This study aims to design and evaluate a psychological intervention program to improve sleep quality and reduce insomnia symptoms in female university students aged 18-25, with the purpose of strengthening cold executive functions and analyzing its impact on academic performance.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
25 Years
Healthy volunteers
No
Inclusion Criteria: * Sex: Female * Age: 18-25 * Chronic insomnia diagnosed by assessment tool. * Must be university students of any major. * Must have time available to participate in at least 80% of the sessions. * Must explicitly express their desire to participate by signing the informed consent form. Exclusion Criteria: * Sex: Women in transition or men. * Psychiatric or neurological diagnosis other than insomnia. * Use of psychoactive substances. * Under pharmacological treatment for any medical, psychiatric, or neurological condition, including insomnia. Elimination Criteria: * Voluntary withdrawal * Absence from more than 20% of sessions. * Receiving a diagnosis and/or treatment that interferes with the variables evaluated and addressed.

Primary outcome measure(s)

  • Sleep Quality — Pre-post intervention evaluation, after 8 weeks.
    Pittsburgh Sleep Quality Index (PSQI; Buysse et al., 1989) is a self-report instrument designed to assess sleep quality and sleep disturbances over the past month. It evaluates seven components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. These components generate an overall score that allows differentiation between people who sleep well and people who sleep poorly. Its psychometric properties have demonstrated adequate levels of reliability and validity. Furthermore, it exhibits good sensitivity and specificity for identifying clinically significant sleep problems and is therefore considered a valid and reliable instrument for assessing sleep quality. It evaluates sleep over the past month using 19 self administered questions, with a total score ranging from 0 to 21 points. An overall score \> 5 indicates poor sleep quality while a score ≤ 5 suggests adequate sleep quality

Trial sites (1)

FacilityCityRegionStatus
Universidad Autónoma de Baja California Mexicali Estado de Baja California
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07529652 on ClinicalTrials.gov ↗ ← All trials in Mexico